Orchestra BioMed Holdings, Inc. OBIO

5.95 0.00 0.00% as of 25 Sep
Market cap
$366.0M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — — — 0.00 0.00 0.00 0.00
P/S ratio
— — — — 42.60 105.69 55.83 5.92
P/FCF ratio
— — — — 0.00 0.00 0.00 0.00
P/Operating CF
— — — — (17.21) (26.58) (10.88) (87.29)
P/B ratio
— — — — 2.86 4.29 4.47 3.70
Price to Tangible BV
— — — — 2.86 4.29 4.47 3.70
EV/Sales
— — — — 21.57 74.36 35.92 3.16
EV/EBITDA
— — — — 0.00 0.00 0.00 0.00
EV/Operating CF
— — — — (2.60) (4.45) (1.87) (2.16)
EV/FCF
— — — — (2.55) (4.44) (1.86) (2.14)
Quick Ratio
— — 17.03 10.60 4.52 7.82 4.13 6.37
Current Ratio
— — 18.06 10.88 4.56 7.95 4.27 6.45
Net Debt/EBITDA
— — 11.26 4.44 2.30 1.71 0.82 1.80
Debt/Assets
0.00% 0.00% 0.00% 0.00% 9.93% 0.00% 18.76% 12.42%
Debt/Equity
— — 0.00 0.00 0.18 0.00 0.43 0.27
Asset Turnover
— 0.00 0.00 0.00 0.03 0.03 0.03 0.35
Operating CF/Net income
— — 1.49 0.72 0.87 0.94 0.83 0.92
Capex/Depreciation
— — — — (1.54) (0.20) (0.85) (0.90)
Interest Coverage
— — 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— — 4.62% 10.09% (138.33%) (81.47%) (120.84%) (122.40%)
ROA
— 0.00% (0.21%) (0.23%) (26.11%) (51.49%) (71.21%) (55.44%)
ROIC
— — 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
— — (8.55%) (23.16%) (49.71%) (62.03%) (112.28%) (57.01%)
Average Days of Receivables
— — — — 9.92 13.09 12.73 1.04
Research and Development Expense of Revenue
— — — — 621.14% 1,225.43% 1,622.59% 173.78%
Selling, General and Administrative Expense of Revenue
— — 0.00% 0.00% 397.23% 733.99% 907.16% 80.38%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— — — — 96.60% 276.27% 402.39% 35.77%
Graham Net Nets
— — — — 0.28 0.21 0.18 0.24
Graham Number
— — — — 0.00 0.00 0.00 0.00
Earnings Yield
— — — — (22.33%) (17.08%) (41.75%) (27.23%)
Free Cash Flow Yield
— — — — (19.86%) (15.84%) (34.52%) (24.96%)
Revenue per Share
— — 0.00 0.00 0.24 0.08 0.07 0.70
Operating CF per Share
— — (0.02) (0.01) (1.95) (1.39) (1.37) (1.03)
Capex per Share
— — 0.00 0.00 (0.04) 0.00 (0.01) (0.01)
Free Cash Flow per Share
— — (0.02) (0.01) (1.99) (1.39) (1.38) (1.04)
Cash per Share
— — 0.13 0.09 5.59 2.64 1.81 2.23
Shareholders Equity per Share
— — (0.23) (0.19) 3.50 2.05 0.90 1.12
Interest Debt per Share
— — 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— — (0.23) (0.19) 3.50 2.05 0.90 1.12
Free Cash Flow
— — (0.26) (0.27) (29.88) (46.20) (50.85) (49.45)
Working Capital
— — 2.03 1.64 66.12 77.91 52.96 91.18
Capital Expenditures
— — — — (0.59) (0.08) (0.29) (0.49)
Net Current Asset Value
— — (163.57) (163.96) 41.65 61.95 25.96 46.62
EV/EBIT
— — — — 0.00 0.00 0.00 0.00
Capex to Sales
— — — — 0.17 0.03 0.11 0.01
Net Profit Margin
— — 0.00% 0.00% (951.26%) (1,779.71%) (2,313.27%) (158.16%)
Price to Operating Income
— — — — 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
— — — — 0.26 0.31 0.24 0.32
Cash ROIC
— — 16.83% 12.45% (21.11%) (30.46%) (45.54%) (29.07%)
Accounts Receivable Turnover
— — — — 0.00 28.31 27.62 358.10
Accounts Payable Turnover
— — 0.00 0.00 0.11 0.05 0.05 0.03
Inventory Turnover
— — — — 0.00 0.88 1.28 0.79
Average Days of Payables
— — 0.00 0.00 6,864.08 5,690.86 9,185.83 11,708.82
Days of Inventory on Hand
— — — — 477.44 286.51 309.53 595.53
Average Receivables
— — — — — 0.10 0.10 0.09
Average Payables
— — 0.01 0.01 1.98 3.43 4.02 5.61
Average Inventory
— — — — — 0.21 0.16 0.24
Average Assets
— 0.00 81.08 161.99 128.70 95.39 85.69 95.52
Average Common Equity
— — (3.75) (3.75) 24.30 60.29 50.50 43.26

Fold the line items

Columns are period end dates